Sun Pharma Announces US Launch of Authorized Generics for Benicar®, Benicar HCT® , Azor®  and Tribenzor®

Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all strengths of: 

 

• Olmesartan Medoxomil tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Benicar®  (olmesartan medoxomil) tablets;
• Olmesartan Medoxomil-Hydrochlorothiazide tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Benicar HCT®  (olmesartan medoxomil-hydrochlorothiazide) tablets;
• Amlodipine Besylate-Olmesartan Medoxomil tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Azor ® (amlodipine and olmesartan medoxomil) tablets; and
• Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Tribenzor® (olmesartan medoxomil, amlodipine, hydrochlorothiazide) tablets. 

The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly owned subsidiary and Daiichi Sankyo Inc., which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period. Benicar® , Benicar HCT® , Azor® – and Tribenzor®  recorded US sales of approximately US$ 2.5 billion for the 12 months ending August 31, 2016, as per IMS Health. 

About Sun Pharmaceutical Industries Ltd.
Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma’s global presence is supported by 47 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2016 are approximately US$ 4.3 billion, of which US contributes US$ 2.1 billion. 

In India,the Company enjoys leadership across 12 different classes of doctors with 32 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 8% of annual revenues.For further information please visit www.sunpharma.com  

Contacts: Sun Pharma

Nimish Desai 
Tel +91 22 4324 4324, Xtn 2778 
Tel Direct +91 22 4324 2778 
Mobile +91-98203 30182 
E mail nimish.desai@sunpharma.com 

Frederick Castr
Tel +91 22 4324 4324, Xtn 277
Tel Direct +91 22 4324 277
Mobile +91 99206 65176
E mail frederick.castro@sunpharma.com